Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Celcuity Inc (NQ: CELC ) 17.04 -0.29 (-1.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Celcuity Inc < Previous 1 2 Next > Celcuity Inc. Announces $50 Million Private Placement October 18, 2023 Via ACCESSWIRE Celcuity Set to Join Russell 2000 and 3000 Indexes June 20, 2023 Via ACCESSWIRE Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences May 24, 2023 Via ACCESSWIRE Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates May 15, 2023 Via ACCESSWIRE Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress May 12, 2023 Via ACCESSWIRE Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors September 14, 2022 Via ACCESSWIRE Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call May 08, 2023 Via ACCESSWIRE Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress May 08, 2023 Via ACCESSWIRE Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 April 18, 2023 Via ACCESSWIRE Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference April 12, 2023 Via ACCESSWIRE Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update March 23, 2023 Via ACCESSWIRE Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call March 16, 2023 Via ACCESSWIRE Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 March 15, 2023 Via ACCESSWIRE Celcuity to Participate in Cowen's 43rd Annual Health Care Conference March 01, 2023 Via ACCESSWIRE Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium February 16, 2023 Via ACCESSWIRE Celcuity Closes $100 Million Private Placement December 12, 2022 Via ACCESSWIRE Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium December 09, 2022 Via ACCESSWIRE Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer December 07, 2022 Via ACCESSWIRE Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium November 22, 2022 Via ACCESSWIRE Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference November 10, 2022 Via ACCESSWIRE Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 10, 2022 Via ACCESSWIRE Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call November 03, 2022 Via ACCESSWIRE Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update August 11, 2022 Via ACCESSWIRE Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call August 04, 2022 Via ACCESSWIRE Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference August 03, 2022 Via ACCESSWIRE Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer July 18, 2022 MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today... From Celcuity Inc. Via AccessWire Exposures Product Safety Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences May 26, 2022 MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates May 16, 2022 - Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast... From Celcuity Inc. Via AccessWire Exposures Product Safety Celcuity Inc. Announces $100 Million Private Placement May 16, 2022 Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a... From Celcuity Inc. Via AccessWire Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call May 09, 2022 MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.